We studied the effect of monoclonal antibody protein dose on the uniformity of radioiodinated antibody distribution within tumor masses using quantitative autoradiography. Groups (n = 11-13/group) of athymic nude mice with subcutaneous HTB77 human ovarian carcinoma xenografls were injected intraperitoneally with an 125I-labeled anticarcinoma-associated antigen mufine monoclonal antibody, 5G6.4, using a high or a low protein dose (500 gg or 5 gg). At 6 days post-injection the macroscopic and microscopic intratumoral biodistfibution of radiolabeled antibody was determined. The degree of heterogeneity of the labeled antibody distribution within each tumor was quantified and expressed as the coefficient of variation (CV) of the activity levels in serial histological sections. Tumors from mice given the 500-gg protein doses had substantially lower CV values, 0.327+0.027, than did tumors from animals given 5-gg protein doses, 0.458 + 0.041, (P = 0.0078), indicating that the higher protein dose resulted in more homogeneous distribution of radioactivity in tumors than did the lower dose. While the percentage of the injected dose reaching the tumor was comparable between groups, injecting the higher dose of protein resulted in significantly lower tumor to non-tumor uptake ratios than those obtained for the lower protein dose. These data indicate, in this system, that to achieve more uniform intratumoral antibody (and radiation for radioimmunotherapy) delivery, a relatively high protein dose must be administered. However, to obtain this increased uniformity, a substantial drop in tumor/background uptake ratios was seen. Quantitative autoradiographic evaluation of human tumor xenografts is a useful method to assess the intratumoral distribution of antibodies.
Introduction
Monoclonal antibodies as carriers of radionuclides, drugs, and toxins are being intensively investigated for their use in both cancer imaging and therapy [27] . Maximal antibody delivery to tumors with minimal uptake in normal tissues is desirable for both imaging and therapy. For antibody conjugate therapy, however, the uniformity of antibody distribution within the tumor mass itself is an additional concern. A homogeneous intratumoral distribution is desirable and probably necessary for many therapeutic applications. This is because even though an appropriately labeled antibody may be lethal to all cancer cells it binds to, if its delivered toxicity is unable to reach all regions within a tumor mass, some cells may survive and continue to grow. With radioimmunotherapy, the use of higher-energy emitters such as 90y may allow for successful tumor treatment despite an inhomogeneous distribution because the emitted particles travel a substantial distance, but for lower-energy ~ and c~ emitters, drugs, and toxins, adequate delivery of antibody to most or all cells in a tumor is probably obligatory for successful treatment [10] .
The distribution of monoclonal antibodies within tumors may be affected by numerous biological factors that influence the accessibility of antibodies to antigenic sites (e. g. tumor blood flow, tumor vascularity, vascular permeability, antibody molecular mass, antigen, antibody affinity and tumor interstitial pressure) [8, 12, 13, 15, 18, 22] . It has been reported that higher antibody uptake and a more uniform distribution across tumor masses was achieved when the tumor was incubated with antibody in vitro than following systemic administration in vivo. These results indicate that, in vivo, the antigenic sites are commonly not fully saturated [23] . One potential method to improve antibody delivery to the tumor antigenic sites is to administer higher levels of antibody protein so that antibody might diffuse more deeply into tumors. Some reports indicate that antibody protein dose does not have a significant effect upon the percentage of the injected dose of iodinated antibody reaching either the tumor xenografts or normal tissues in cancer models [24, 30] . However, when an lnIn-labeled anti-carcinoembryonic (CEA) antigen monoclonal antibody is used in patients, an increase in the accumulation of activity in the tumor relative to the background levels has been seen when the protein dose was increased [20] . Others have shown, in an animal model of colon cancer, that an anti-(colorectal cancer) monoclonal antibody, given at high protein doses, targets less well than at a lower protein dose, probably because of antibody saturation of tumor antigenic sites [6] . Thus, some variability of the effect of protein is present, depending on the system studied.
The effects of the protein dose on the distribution of radioantibody within the tumor itself have not been previously studied quantitatively. Initial qualitative autoradiographic techniques have, however, detected concentrations of radioantibodies primarily in perivascular areas in tumors following intravenous antibody delivery, probably because of the binding of high-affinity antibody [5] . Recently, qualitative ilmnunohistochemical studies have demonstrated that a more uniform intratumoral distribution of antibody has been achieved with a higher administered antibody protein dose in animal studies [ 19] . In addition, using qualitative autoradiographic techniques, Blumenthal et al. were able to demonstrate that, for two specific antibodies to CEA that demonstrated good targeting, the intratumoral antibody distribution following i.v. administration appeared to be more uniform at high, rather than low, protein doses in a colon cancer xenograft system.
We evaluated the effect of antibody protein dose on the delivery and distribution of radioactivity within ovarian adenocarcinoma masses, studied with a radioiodinated anticarcinoma monoclonal antibody, 5G6.4 [31] , injected into nude mice bearing subcutaneous human ovarian carcinoma xenografts. Whole-body and intratumoral distributions of the labeled antibody were digitally quantified using a computer image-analysis system. This quantitative method was developed to provide an objective means for comparing the antoradiographs obtained from the different tumors [35] . Our initial results with this method were recently reported in abstract form [34] .
Materials and methods
Monoclonal antibody. 5G6.4 is an IgG2ak murine monoclonal antibody reactive with epithelial carcinomas [31] . It was produced in mouse ascites and purified by staphylococcal protein A column chromatography, eluting at pH 5. Protein concentration was determined by the colorimetric method developed by Bradford using bovine IgG (Bio-Rad) as reference standard [3] . The purity of the 5G6.4 preparation was verified by sodium doclecyl snifate/polyacrylamide gel electrophoresis under reducing conditions. Antibody radiolabeling. The iodogen method was used to label the antibody with sodium [125I]iodide (ICN) [7] . The radiolabeling reaction consisted of 2.69 mCi 125I reacted with a protein mass of 94.5 gg at a concentration of 10.5 mg/ml. The preparation was purified via anion-exchange chromatography (Bio-Rad AG l-X8, 200-400 mesh). Freeiodine contamination was determined by silica gel TLC; only 2% free iodine was measured in the final preparation used for this study. Immunoreactivity was confirmed by a direct cell binding assay, which was performed with viable human ovarian carcinoma (HTB77 IP3) target Biodistribution study. Intraperitoneal injections of the 125I-5G6.4 were administered, taking advantage of egress of the antibody from the peritoneal cavity to the systemic circulation [32] . An initial pilot study with three groups of mice receiving dosages of 5, 50, or 500 gg 5G6.4 was performed to test the feasibility of the method. Subsequently, in the definitive study, the mice were divided into two groups: both groups received approximately 75 gCi 125I-5G6.4 each but at different protein doses: 5 gg (n = 11) and 500 btg (n = 13). To prepare the 500-gg doses, 5 gg radiolabeled antibody was mixed with 495 gg unlabeled 5G6.4 antibody prior to injection. All mice were sacrificed 6 days after injection and tissues were weighed and counted in a gamma counter. The percentage of the injected dose per gram was calculated using standard techniques [28, 29, 32] .
Quantitative autoradiography. Excised tumors were quickly frozen at -70 °C. Representative frozen sections of each tumor, primarily from equatorial regions, were cut at 12-gm thickness at a minimum distance of 600 gm from one another. Contact autoradiography was performed by exposing Kodak Xar5 film to the sections for 64 h at room temperature [14] . Standards correlating activity in gCi/g with film absorbance were obtained from autoradiographs of frozen sections of the livers of two BALB/e mice injected with 100 ~tCi and 200 gCi of the same 125I-5G6.4 preparation used in the biodistribution study. Livers were weighed, counted, frozen, and sectioned at 12 gin. A timed course of exposure (between 2 h and 128 h) was used to obtain a standard gray scale correlating the activity with absorbance for each piece of film used. The film was Examples of the quantitative autoradiographic analysis used in this study. A A representative section from a tumor removed from a mouse that received 500 gg 125I-5G6.4. The coefficient of variation for this section was 0.347. B A section from a tumor removed from a mouse that received 5 gg 125I-5G6.4. The coefficient of variation for this section was 0.504. a, The section stained with hematoxylin and eosin; b, the autoradiograph of the same section; c, the image generated from the video densitometer computer system; d, the plot of the number of pixels in the tumor at each activity level detected by the densitometer Medical Center. Relative absorbance was measured by an International Imaging System model 75 image processor using a Dage-MTI Newvicon camera with a 25-mm 1 : 1.4 Vidicon lens. The system is connected to a Masscomp 500 dual processor 68 000 based computer, which runs a real-time version of the Unix operating system. Images were digitized into a 512 x 512 array of pixels (point measurements) with 256 absorbance levels. The width of each pixel square was 155 ~tm. Prior to analysis the system was normalized to ensure that each pixel had a linear intensity/absorbance response. This was done by taking a series of images from the brightest background field that the camera analyzed (in this case a blank piece of film) to the darkest (a black field). A computer program then corrected every pixel for a linear response. Each absorbance level was then automatically converted to a specific activity level (gCi/g) by comparison to the standard gray scale.
This process enabled us to assign specific radioactivity levels to every pixel in the autoradiographic images. The outline of each autoradiographic image was carefully traced so that only regions correlating to tumor were analyzed. Plots of activity level (gCi/g) versus area of the cross-section (pixels) were generated for each tumor. The heterogeneity of intratumoral distribution is expressed by the standard deviation from the mean activity level. In order to compare different tumors, the coefficient of variation (CV) of tumor uptake of radioactivity was calculated for each of them. Tumors with identical antibody distribution patterns but different overall uptakes will exhibit different mean antibody uptake percentages and differ in their standard deviations. The coefficient of variation, which is obtained by dividing the standard deviation by the mean tumor uptake of radioactivity for these tumors is, however, identical (0.408) (Fig. 1) . Such a measure allows one to compare the uniformity of radioantibody uptake between different tumors, even if the absolute tumor uptake is substantially different. A low CV indicates less variation in activity of different regions in a tumor and therefore a more homogeneous intratumoral distribution. An average CV was obtained from the multiple sections obtained from each tumor in each group. The difference between the two groups was analyzed by an unpaired, one-tail t-test.
Immunohistochemistry. Two to three representative sections of each autoradiographed tumor were stained with hematoxylin and eosin to assess architecture and extent of necrosis. Additional HTB77 IP3 tumors were grown for immunohistochemical study in four nude mice, which were not injected in vivo with radiolabeled monoclonal antibodies. The tumors were removed and frozen in isopentane cooled by liquid nitrogen. Cross-sections, 10 ~tm thick, from the middle of the tumors were cut in the cryostat at -20 ° C and mounted on poly-L-lysine-coated slides. The sections were air dried and kept at -70 ° C until stained.
Thawed sections were fixed for 10 min in buffered formalin (4% in phosphate-buffered saline, PBS, pH 7.0) and were stained using a modification of the indirect immunoperoxidase method of Hsu [ 11] : sections were incubated with a 10 gg/ml solution of biotinylated 5G6.4 (ETAC method) [4] in diluent (4% bovine serum albumin, 1% horse serum in PBS) for 30 rain, washed with PBS and then further incubated with avidin-peroxidase conjugate for 30 min (Vectastain Kit, Vector). The sections were then washed with PBS and the bound antibody was visualized with diaminobenzidine and counterstained with hematoxylin. Sections incubated with the diluent alone were used as controls.
Results
On microscopic examination, the tumors were glandular ( Fig. 2A, B) and did not contain large areas of necrosis; however, scattered small necrotic foci could be seen throughout the entire tumor. All tumors that were i m m unostained expressed binding sites for this antibody. Of the tumor cells in the sections, 7 0 % -9 0 % reacted with the 5G6.4 antibody (Fig. 3 A, B) . Stained granules were seen throughout the cytoplasm of most of the cells. In some cells, concentrations of stained granules were observed along the cell membranes (Fig. 4A, B) . No staining was seen in the control sections (Figs. 3, 4) or in the connective tissue of the positive sections (Fig. 4) .
The in vivo intratumoral distribution of the labeled antibody, evaluated by quantitative autoradiography, was Fig. 2A, B . The n u m b e r of animals employed in the initial pilot study with 5 -, 50-and 500-gg dose groups (n = 4, 5) was too small to achieve statistical significance; however, the results from this feasibility study did suggest that the CV of the activity levels obtained in autoradiographs from tumors treated with 500 gg (0.289 + 0.06 SEM) was much smaller than in either the 5-or 50-gg groups. The differences between the CV of the 5-and 50-gg groups, although not necessarily unworthy of future investigation, were not felt to be significant (0.401___0.04 and 0 . 5 0 1 + 0 . 0 5 respectively), especially considering the variability within each group. Therefore, in the definitive study we expanded the number of animals in the 5-gg and 500-gg groups to 11-13/group for further evaluation. The uniformity of radioantibody distribution in the 500-gg protein dose group was substantially greater than in the 5-btg protein dose group at the 6-day time point after injection. This relatively long time after injection was chosen, as at this time tumor-specific binding predominates [32] . The mean CV of the activity levels of the autoradiographs from the 500-gg group was 0.327 _+ 0.027 and that of the 5-gg group was 0.458 _+ 0.044 (P = 0.0078) (P <0.01) ( Table 1) . These results provide strong support for our hypothesis that a more uniform intratumoral distribution of antibody is achieved when higher protein doses are administered. Changing the protein dose from 5 gg to 500 gg did not significantly affect the fraction of the injected dose reaching the tumor. However, increased amounts of radioactivity were found in the normal tissues at the higher doses, probably because of higher blood levels ( Table 2) . As a result, tumor to normal tissue ratios of delivered radioactivity were significantly lower at the 500-gg level than at the 5-gg level (P <0.05). Tumor size was not found to be a factor affecting the intratumoral distribution in this study, there being no correlation between the CV values of the intratumoral radioactivity and the tumor weights. The mean tumor weights were comparable between the groups: 5 gg, 0.971 +0.206 g; 500 gg, 0.885 _+0.199 g.
Discussion
Our study quantitatively determined the effect of antibody protein dose on overall and intratumoral distribution of 125I-5G6.4 monoclonal antibody in nude mice with human ovarian carcinoma xenografts 6 days after injection. Our study differs from prior theoretical and qualitative studies in that we applied this quantitative imaging method to assess this question objectively [2, 8, 19] in large groups of animals with multiple sequential sections from each tumor, so that over 240 different tumor sections were quantitatively assessed. With this quantitative method, we have been able to demonstrate that increasing the protein dose from 5 gg to 500 gg in this system significantly increases the uniformity of intratumoral distribution of antibody. The quantitative approach removes any potential subconscious or conscious observer bias in the interpretation of qualitative studies. Our study further demonstrates that this increased uniformity comes with a price of a decrease in target to background ratios.
Our quantitative results are somewhat similar to those recently reported by Blumenthal and colleagues, in which two different monoclonal antibodies reactive with carcinoembryonic antigen were qualitatively shown to have a more uniform intratumoral distribution when a high pro- antibody, 5G6.4, at the 500-gg injected protein dose in the normal tissues at sacrifice. No significant difference was found between the two groups in the amount of dose reaching the subcutaneous tumor xenografts tein dose rather than a low dose was used [2] . These investigators, however, were unable to demonstrate improved intratumoral uniformity of uptake with higher protein doses of a nonspecific antibody where uniform uptake was seen, even with a low protein dose and for a specific antibody that targeted tumor less well than with their best reagents. The improved homogeneity in intratumoral uptake of radioantibody we demonstrated, even with relatively low target to background ratios, indicates that protein dose may have a substantial effect on targeting at the microscopic level, even in systems where antibody targeting is not optimal. It is likely that the lower tumor to normal organ ratios seen in our animals at high protein doses were due to partial or complete accessible tumor antigenic saturation at the 500-gg dose. Of note, however, is that our percentage injected dose per gram in the tumor did not actually fall at higher protein doses, rather the percentage uptake in normal tissues increased. It is thus possible that a component of the decrement in target to background ratios at the high protein dose was due to higher blood levels of radioactivity in the high-protein dose group because of the genetic background of the nude mice (Swiss) that were used and the IgG2a isotype of the 5G6.4 antibody.
Rapid blood clearance of IgG2a monoclonal antibodies when low protein doses (<100 gg) are given to nude mice has been reported [25] . This is probably because mouse IgG2a are selectively cleared by the liver and spleen in these animals. Higher protein doses (>100 gg) were reported to block the rapid clearance of IgG2a and result in higher blood radioantibody levels [25] . Higher blood radioantibody levels logically can result in higher delivery of antibody to normal tissues. We did not observe (at the 6-day time point we examined), an increase in splenic or hepatic radioactivity in the low protein dose group compared to the higher protein dose group. Six days post-injection may not be the optimal time to detect increased 125I uptake in the liver and spleen, however. At this late time, dehalogenation of antibody may have occurred, particularly in the liver, which could mask increased targeting to these structures.
It is possible that antibody cross-reactivity with low levels of circulating antigen and attendant rapid clearance of antibody antigen complexes could have occurred at our lower protein doses, which were largely blocked at the high protein dose. We have, however, not been able to demonstrate circulating antigen in this system (Wahl et al. unpub- lished data) and we do not believe this latter suggestion explains our findings.
Our in vivo data, showing improved homogeneity of tumor uptake, are parallel to in vivo results and also similar to in vitro data reported by Kwok, who used multicellular spheroids and showed that tumor antigenic sites were saturable [2, 17] . It has, however, been somewhat difficult to demonstrate tumor saturation in vivo. Indeed, prior studies by ourselves in another antibody/tumor system showed no clear change in the percentage injected dose per gram of iodinated intact antibody reaching tumors in a melanoma xenograft system at protein doses ranging from 6.25 gg to 1.875 mg 125I-labeled 225.285 or 763.24 T monoclonal anti-melanoma monoclonal antibodies [30] .
Increasing the antibody protein dose from 0.001 mg to 1.0 mg did not improve tumor to normal tissue ratios nor improve external scintigraphic contrast of human colonic cancer xenografts on hamsters [24] . More recent studies, however, were performed in a nude mouse where the animal weight was substantially lower and tumor saturation could, and was, more easily accomplished [2] . Only slightly increased levels of 13q-labeled antibody reached murine lymphomas at progressively higher protein doses [1] . A decline in fractional anti-(colorectal cancer) monoclonal antibody uptake to colon cancer xenografts in hamsters at protein doses above 100 p.g was seen in another study, but full tumor saturation was not achieved at this dose [6] .
These data indicate that, in selected animal models, some element of tumor saturation is possible with high doses of antibody protein, though very high protein levels are generally required. Thus, our quantitative experimental results partially support antibody localization models and concepts previously outlined by several groups [2, 8, 9, 12, 13, 17, 19, 26] . These concepts suggest that higher protein doses should improve the uniformity of antibody distribution in tumors and result in increased penetration of antibody away from blood vessels into tumors. We did not, however, observe substantial difficulty in permeating the central portions of our tumor xenografts with antibody. Certainly, additional studies with antibody fragments and at other time points would be useful to address whether better penetration is possible, as has been suggested in theoretical and initial qualitative autoradiographic studies [8, 211 .
The implications of uniform distribution of radioactivity within a tumor are somewhat dependent on the choice of radionuclide for tumor therapy [10, 16] . If a low protein dose of antibody is used, it would appear from our study and others that much of the antibody molecule will bind to tumor-associated antigen located near the vessels that enter 371 the tumor. With higher protein doses, greater diffusion seems to be achievable. This latter more homogeneous distribution would probably be necessary for treatment with low-energy [~ particles or o~ particles, or drug-antibody conjugates, to be successful. For therapy with more energetic ~ emitters, such as ytterium-90, a less uniform distribution of radiopharmaceuticals in tumors may be acceptable [10, 16] . For tumor imaging, high-level localization of antibody to the tumor would be necessary, while uniform distribution of radioactivity within the tumor would be less essential. Thus, lower protein doses may be perfectly appropriate for tumor imaging and may offer advantages over higher protein doses.
The precise degree of homogeneous intratumoral radioactivity distribution of antibody conjugates required for therapeutic efficacy remains to be determined. Quantitative autoradiographic studies such as ours may be helpful in addressing this issue.
In summary
Our study demonstrates that, in a human ovarian carcinoma xenograft system in nude mice, a relatively low protein dose (5 gg) of radiolabeled antibody results in significantly superior targeting compared to a higher (500 gg) protein dose. The higher protein dose, however, results in a significantly more uniform distribution of radioactivity within the tumor than the lower dose. Thus, an optimal protein dose, at least in this animal system, may exist for therapy while another optimal protein dose may exist for imaging. Additional quantitative studies in other animal models and patients, which address this issue, will be of interest.
